These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18359669)

  • 1. Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Anscher MS; Oleson JR
    Brachytherapy; 2008; 7(2):206-11. PubMed ID: 18359669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
    Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
    McMullen KP; deGuzman AF; McCullough DL; Lee WR
    Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
    Papagikos MA; Deguzman AF; Rossi PJ; McCullough DL; Clark PE; Lee WR
    Brachytherapy; 2005; 4(4):252-8. PubMed ID: 16344254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between Day 0 dosimetric parameters and biochemical relapse-free survival in patients treated with transperineal permanent prostate interstitial brachytherapy with (125)I seeds.
    Garrán C; Ciérvide R; Cambeiro M; Moreno-Jiménez M; Ramos LI; Martínez-Monge R
    Brachytherapy; 2010; 9(1):8-14. PubMed ID: 19846350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2006 May; 79(2):185-9. PubMed ID: 16701911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
    Papagikos MA; Rossi PJ; Urbanic JJ; deGuzman AF; McCullough DL; Clark PE; Lee WR
    Am J Clin Oncol; 2007 Apr; 30(2):199-204. PubMed ID: 17414471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
    Nobes JP; Wells IG; Khaksar SJ; Money-Kyrle JF; Laing RW; Langley SE
    Prostate Cancer Prostatic Dis; 2009; 12(1):61-6. PubMed ID: 18427571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
    Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
    Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer.
    Rossi PJ; Clark PE; Papagikos MA; McCullough DL; Lee WR
    Urology; 2006 Feb; 67(2):349-53. PubMed ID: 16461084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate.
    Quan AL; Ciezki JP; Reddy CA; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; De Oreo G; Klein EA
    Urology; 2006 Dec; 68(6):1237-41. PubMed ID: 17169646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
    Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.
    Bachand F; Martin AG; Beaulieu L; Harel F; Vigneault E
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):679-84. PubMed ID: 18963537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L; Huang D; Fearn P; Kattan MW
    Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.